Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia
Archive ouverte
Letestu, Rémi | Dahmani, Abdelmalek | Boubaya, Marouane | Baseggio, Lucile | Campos, Lydia | Chatelain, Bernard | Debliquis, Agathe | Drénou, Bernard | Jacob, Marie-Christine | Legac, Eric | Le Garff-Tavernier, Magali | Lhoumeau, Anne-Catherine | Quiney, Claire | Robillard, Nelly | Ticchioni, Michel | Aanei, Carmen | Katsahian, Sandrine | Delepine, Roselyne | Vaudaux, Sandrine | Rouillé, Valérie | Béné, Marie-Christine | Dartigeas, Caroline | van den Neste, Eric | Leprêtre, Stéphane | Feugier, Pierre | Cartron, Guillaume | Leblond, Véronique | Lévy, Vincent | Cymbalista, Florence | Cailleres, Sylvie | Damaj, Gandhi | Royer, Bruno | Gardembas, Martine | Dib, Mamoun | Truchan-Graczyk, Matgorzata | Hunault, Mathilde | Foussard, Charles | Corront, Bernadette | Parry, Anne | Orsini-Piocelle, Frédérique | Trouillier, Sébastien | Slama, Bohiane | Lepeu, Gérard | Zerazhi, Hacene | Boulat, Olivier | Azzedine, Ahmed | Araujo, Carla | Banos, Anne | Bauduer, Frédéric | Dutel, Jean-Luc | Ghomari, Kamel | Deconinck, Eric | Brion, Annie | Vuillier, Jacqueline | Saad, Alain | El Yamani, Abderrazak | Rodon, Philippe | Soubeyran, Pierre | Etienne, Gabriel | Dilhuydy, Marie-Sarah | Bouabdallah, Krimo | Leguay, Thibaut | Chouffi, Bachra | Pollet, Bertrand | Maakaroun, Abdallah | Guillerm, Gaëlle | Berthou, Christian | Cheron, Nathalie | André, Marc | Vilque, Jean Pierre | Fruchart, Christophe | Voillat, Laurent | Pica, Gian Matteo | Corm, Sélim | Micléa, Jean-Michel | Souleau, Bertrand | Molucon-Chabrot, Cécile | de Renzis, Benoit | Tournilhac, Olivier | Bay, Jacques-Olivier | Chaleteix, Carine | Guieze, Romain | Fleury, Joel | Precupanu, Cristina | Bouledroua, Selwa | Haiat, Stéphanie | Petitdidier, Charlotte | Dupuis, Jehan | Belhadj, Karim | Casasnovas, Olivier | Bastie, Jean-Noel | Ferrant, Emmanuelle | Gholam, Dany | Molina, Lysiane | Garban, Frédéric | Tiab, Mourad | Maisonneuve, Hervé | Villemagne, Bruno | Jacomy, Dominique | Besson, Caroline | Tertian, Gérard | Laribi, Kamel | Morel, Pierre | Cazin, Bruno | Moreau, Stéphane | Reminieras, Liliane | Rapp, Marie-José | Moreau, Philippe | Sebban, Catherine | Michallet, Anne-Sophie | Salles, Gilles | Broussais, Florence | Aurran-Schleinitz, Thérèse | Coso, Diane | Abarah, Wajed | Kulekci, Claire | Dorvaux, Véronique | Carassou, Philippe | Guibaud, Isabelle | Christian, Bernard | Graux, Carlos | Rossi, Jean-François | Quittet, Philippe | Dubois, Alain | Eisenmann, Jean-Claude | Morineau, Nadine | Mahé, Béatrice | Karsenti, Jean-Michel | Jourdan, Eric | Legouffe, Eric | Alexis-Vigier, Magda | Boulet, Jean-Michel | Aoudjhane, Malek | Thiéblemont, Catherine | Andreoli, Anna Lisa | Dreyfus, François | Choquet, Sylvain | Maloum, Karim | Merle-Béral, Hélène | Vekhoff, Anne | Decaudin, Didier | Brault, Philippe | Delarue, Richard | Janvier, Maud | Soussain, Carole | Vallantin, Xavier | Sanhes, Laurence | Dreyfus, Brigitte | Tomowiak, Cécile | Benramdane, Riad | Gonzalez, Hugo | Blaise-Brenna, Anne | Kolb, Brigitte | Delmer, Alain | Dauriac, Charles | Houot, Roch | Escoffre-Barbe, Martine | Lamy, Thierry | de Guibert, Sophie | Bernard, Marc | Grosbois, Bernard | Brehar, Oana | Morice, Patrick | Guyotat, Denis | Jaubert, Jérome | Portois, Christelle | Fornecker, Luc-Matthieu | Herbrecht, Raoul | Bilger, Karin | Ame, Shanti | Ysebaert, Loic | Godmer, Pascal | Jardel, Henry
Edité par
CCSD ; Springer Nature -
International audience.
Measurable residual disease (MRD) status is widely adopted in clinical trials in patients with chronic lymphocytic leukemia (CLL). Findings from FILO group trials (CLL2007FMP, CLL2007SA, CLL2010FMP) enabled investigation of the prognostic value of high-sensitivity (0.7 × 10-5) MRD assessment using flow cytometry, in blood (N = 401) and bone marrow (N = 339), after fludarabine, cyclophosphamide, and rituximab (FCR)-based chemoimmunotherapy in a homogeneous population with long follow-up (median 49.5 months). Addition of low-level positive MRD < 0.01% to MRD ≥ 0.01% increased the proportion of cases with positive MRD in blood by 39% and in bone marrow by 27%. Compared to low-level positive MRD < 0.01%, undetectable MRD was associated with significantly longer progression-free survival (PFS) when using blood (72.2 versus 42.7 months; hazard ratio 0.40, p = 0.0003), but not when using bone marrow. Upon further stratification, positive blood MRD at any level, compared to undetectable blood MRD, was associated with shorter PFS irrespective of clinical complete or partial remission, and a lower 5-year PFS rate irrespective of IGHV-mutated or -unmutated status (all p < 0.05). In conclusion, high-sensitivity (0.0007%) MRD assessment in blood yielded additional prognostic information beyond the current standard sensitivity (0.01%). Our approach provides a model for future determination of the optimal MRD investigative strategy for any regimen.
